US chemoproteomics start-up Belharra Therapeutics, has entered into a strategic collaboration with French pharma major Sanofi (Euronext: SAN) to advance the discovery of novel small molecule therapeutics for immunological diseases.
The collaboration will leverage San Diego-based Belharra’s proprietary non-covalent chemoproteomics platform to screen and validate hits against undisclosed Sanofi-designated immunology targets.
Belharra emerged from stealth with a $50 million Series A financing and multi-year collaboration with Roche (ROG: SIX) subsidiary Genentech providing $80 million up front in January this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze